Venrock Adviser, LLC 13F holdings, Q3 2025
Holdings as of September 30, 2025 · filings on SEC EDGAR · latest filing →
Venrock Adviser, LLC disclosed 33 US equity positions worth $1.8bn in its Q3 2025 13F filing. The largest position was APGE at 19.0% of the reported book, followed by METSERA INC and OCUL. Against the Q2 2025 filing, it opened 2 new positions, added to 6 and reduced 6 among the top 33 holdings.
What did Venrock Adviser, LLC own in Q3 2025? Top 33 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2025 |
|---|---|---|---|---|---|---|---|
| 1 | APGE APOGEE THERAPEUTICS INC | Healthcare | 19.0% | $337.4m | 8,493,321 | 0% | held |
| 2 | METSERA INC | 11.0% | $196.3m | 3,750,662 | 0% | held | |
| 3 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 8.7% | $153.9m | 13,161,462 | 3% | added |
| 4 | CDTX CIDARA THERAPEUTICS INC | 5.1% | $90.7m | 946,788 | 48% | added | |
| 5 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 4.7% | $83.8m | 3,882,709 | 0% | held |
| 6 | 4XC1 KALVISTA PHARMACEUTICALS INC | 4.6% | $82.0m | 6,728,985 | 0% | held | |
| 7 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 4.5% | $79.8m | 4,148,428 | 0% | held |
| 8 | ORIC ORIC PHARMACEUTICALS INC | Healthcare | 4.5% | $79.2m | 6,596,885 | 0% | held |
| 9 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 3.7% | $66.0m | 3,226,331 | -20% | reduced |
| 10 | COGT COGENT BIOSCIENCES INC | Healthcare | 3.2% | $57.4m | 4,000,000 | -16% | reduced |
| 11 | CTMX CYTOMX THERAPEUTICS INC | Healthcare | 2.8% | $49.6m | 15,561,500 | 11% | added |
| 12 | ABVX ABIVAX SA | 2.8% | $49.0m | 576,729 | -57% | reduced | |
| 13 | SVRA SAVARA INC | Healthcare | 2.5% | $45.3m | 12,681,043 | 43% | added |
| 14 | SYRE SPYRE THERAPEUTICS INC | 2.5% | $45.0m | 2,685,448 | 0% | held | |
| 15 | ERAS ERASCA INC | Healthcare | 2.2% | $38.9m | 17,857,083 | 0% | held |
| 16 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 2.1% | $37.8m | 960,803 | -4% | reduced |
| 17 | ENGENE HOLDINGS INC | 1.9% | $34.5m | 5,046,414 | 0% | held | |
| 18 | MAZE MAZE THERAPEUTICS INC | 1.8% | $31.9m | 1,230,769 | – | new | |
| 19 | JBIO JADE BIOSCIENCES INC | 1.6% | $27.8m | 3,220,364 | 0% | held | |
| 20 | DYN DYNE THERAPEUTICS INC | Healthcare | 1.5% | $27.5m | 2,173,913 | 0% | held |
| 21 | VOR VOR BIOPHARMA INC | 1.4% | $24.4m | 499,966 | – | new | |
| 22 | UPB UPSTREAM BIO INC | 1.2% | $22.0m | 1,169,298 | -49% | reduced | |
| 23 | ZURA ZURA BIO LTD | Healthcare | 1.1% | $20.1m | 4,631,216 | 0% | held |
| 24 | CATBUSD ASTRIA THERAPEUTICS INC | 1.0% | $17.9m | 2,457,348 | 0% | held | |
| 25 | PHVS PHARVARIS N V | 0.9% | $16.8m | 674,599 | -67% | reduced | |
| 26 | CBIO CRESCENT BIOPHARMA INC. | 0.9% | $16.5m | 1,387,864 | 0% | held | |
| 27 | SEPN SEPTERNA INC | 0.6% | $11.5m | 610,808 | 13% | added | |
| 28 | CGEM CULLINAN THERAPEUTICS INC | Healthcare | 0.5% | $8.2m | 1,379,965 | 0% | held |
| 29 | SRZN SURROZEN INC | 0.5% | $8.2m | 632,931 | 0% | held | |
| 30 | PERCEPTIVE CAP SOLUTIONS COR | 0.4% | $8.0m | 750,000 | 0% | held | |
| 31 | ARTV ARTIVA BIOTHERAPEUTICS INC | 0.3% | $4.6m | 1,609,569 | 0% | held | |
| 32 | TENX TENAX THERAPEUTICS INC | 0.2% | $3.3m | 437,708 | 344% | added | |
| 33 | CASIF CASI PHARMACEUTICALS INC | 0.1% | $1.6m | 987,259 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.